SAB Biotherapeutics, Inc. Common Stock
SABSSAB Biotherapeutics, Inc. (SABS) is a biotechnology company specializing in developing and manufacturing innovative antibody-based therapeutics. The company leverages its proprietary platform to produce fully-human, polyclonal antibodies derived from transchromosomic cattle, aimed at treating infectious diseases and providing immune protection. SAB Biotherapeutics focuses on rapid response to emerging health threats and enhancing immune treatments through its advanced biopharmaceutical technologies.
Company News
SAB Biotherapeutics announced the appointment of David Zaccardelli, Pharm.D. as Board Chair and Rita Jain, M.D. as an independent director, effective immediately. Zaccardelli brings over 20 years of biopharmaceutical executive experience, including leading the successful launch of Ohtuvayre® at Verona Pharma. Jain is a rheumatologist with two de...
SAB Biotherapeutics reported positive Phase 1 trial results for SAB-142, a potential treatment for type 1 diabetes, demonstrating safety, low immunogenicity, and no serum sickness across healthy volunteers and patients.
SILQFi has launched Omni, a new financial platform for small businesses, after acquiring OXO. The platform integrates point-of-sale, procurement, payments, and credit access to streamline merchant workflows and improve capital access in Saudi Arabia.
SAB BIO, a clinical-stage biopharmaceutical company, reported financial results for Q1 2025. The company made progress on its type 1 diabetes program, including positive Phase 1 data for its lead candidate SAB-142. SAB BIO also achieved manufacturing milestones and saw a decrease in R&D and G&A expenses.
SAB BIO, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences to discuss its lead asset, SAB-142, which targets type 1 diabetes with a disease-modifying approach.
